Compare PERF & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERF | ACHV |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 167.6M |
| IPO Year | N/A | N/A |
| Metric | PERF | ACHV |
|---|---|---|
| Price | $1.81 | $4.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 112.2K | ★ 624.2K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.89 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,900,999.00 | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $14.80 | N/A |
| P/E Ratio | $32.93 | ★ N/A |
| Revenue Growth | ★ 14.47 | N/A |
| 52 Week Low | $1.51 | $1.84 |
| 52 Week High | $3.44 | $5.78 |
| Indicator | PERF | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 52.47 |
| Support Level | $1.67 | $3.82 |
| Resistance Level | $1.75 | $4.99 |
| Average True Range (ATR) | 0.08 | 0.30 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 51.85 | 61.54 |
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.